ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Listing requirements for Nasdaq

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Oct 08, 2021 11:38am

182 Views

Post# 33988807

RE:RE:Listing requirements for Nasdaq

Yes, great info indeed, thanks for sharing.

if I'm reading this correctly, I don't think they qualify for any of the four standards unless the market/company values it's IP tangible asset in the 500M range, something we all hope for.

In the meantime, here's what one of the competitors is up to that I found interesting.

https://ca.finance.yahoo.com/news/acumen-announces-first-patient-dosed-120000675.html